A significant breakthrough has been made by researchers at ETH Zurich in the field of targeted drug delivery systems for stroke treatment, utilizing magnetic nanoparticles. This innovative technology allows for precise navigation through the complex networks of blood vessels, which could potentially revolutionize the current treatment methods administered for strokes.

The Challenge of Current Stroke Treatments

Every year, around 12 million people suffer from strokes worldwide, with many either dying or facing permanent impairments. Current therapeutic approaches involve administering thrombolytic drugs designed to dissolve thrombi (blood clots). However, these drugs are delivered systemically, requiring high doses to ensure sufficient concentration at the target site which often leads to severe side effects, including internal bleeding.

To address this pressing issue, researchers have long sought methods that allow for the targeted delivery of pharmaceuticals directly to the thrombus site using microrobots, thereby minimizing systemic exposure and side effects.

Innovative Design of Microrobots

The microrobot developed by the ETH Zurich team comprises a proprietary spherical capsule made of a soluble gel shell that can be manipulated using magnetic fields. Inside this capsule are iron oxide nanoparticles which provide the necessary magnetic properties.

“Because the vessels in the human body are so small, there is a limit to how big the capsule can be. The challenge is to ensure that a capsule this small also has sufficient magnetic properties,” explained Fabian Landers, lead author and postdoctoral researcher.

Combining Imaging and Drug Delivery

In addition to delivering drugs, the microrobots are equipped with a contrast agent that allows doctors to track their movement via X-ray imaging. The researchers focused on the incorporation of tantalum nanoparticles for improved visibility. Professor Bradley Nelson emphasized the "perfect synergy" required between materials science and robotics to achieve this delicate balance.

Mechanism of Drug Release

The microrobots are designed to carry active pharmaceutical ingredients, which may include thrombus-dissolving agents, antibiotics, or tumor medications. The release mechanism involves a high-frequency heating process that activates the magnetic nanoparticles, causing the gel shell to dissolve.

Operational Mechanics

  • Initially, the microrobots are injected into the bloodstream or cerebrospinal fluid via a specially designed catheter.
  • A modular electromagnetic navigation system directs the microrobots to their precise target location.

The catheter design, based on commercially available models, includes an internal guidewire that helps deploy the microrobot through a flexible polymer gripper that releases it when pushed beyond the external guide.

Advanced Navigation Capabilities

One of the major challenges in operating microrobots in the blood vessels is the varying speed of blood flow at different locations. To tackle this, the researchers developed a modular electromagnetic navigation system that integrates three different strategies. This allows the microrobots to navigate efficiently at speeds of up to 4 mm per second while compensating for blood flow velocities that can exceed 20 cm per second.

“The combination of magnetic fields and gradients provides the ideal solution for minimally invasive procedures, as they penetrate deep into the body without harmful effects,” stated Professor Nelson.

Testing and Applications

The researchers utilized realistic models of human vessels to test their microrobots, allowing them to practice and refine their navigation strategies effectively. Following successful trials in these models, animal tests were conducted, demonstrating the microrobots’ capabilities in a clinical-like environment.

Test Environment Outcome
Pig Model Successful navigation and visibility of microrobot
Sheep Cerebrospinal Fluid Proven navigation capabilities in complex anatomical regions

Future Directions and Applications

The applications of these microrobots extend beyond stroke treatment. They hold potential for treating localized infections or tumors by delivering medication directly where it is needed most. The ETH Zurich research team is now focused on preparing for human clinical trials to ensure rapid integration of this technology in operating theaters.

As Landers noted, “What drives us is the knowledge that we have a technology that enables us to help patients faster and more effectively and to give them new hope through innovative therapies.”

Sources

Fabian C. Landers et al, Clinically ready magnetic microrobots for targeted therapies, Science (2025). More Information.

This content is provided for informational purposes and is subject to copyright. For further inquiries, please refer to the respective publication rights and permissions.